Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUASAR2: capecitabine with or without bevacizumab for adjuvant colorectal cancer
ACTRN12606000361505Phase 3Active, not recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Capecitabine + bevacizumab with Capecitabine (2 arms). Primary endpoint: Disease-free survival in all patients. Started Jun 2007; status: active, not recruiting.
02
Drugs
capecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12606000361505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000361505.